Posted from: Monday, March 02, 2015 - 05:12 PM - Present

Pazeo Eye Drops Approved

The U.S. Food and Drug Administration (FDA) approval for Pazeo (olopatadine ophthalmic solution) 0.7% for once-a-day use to relieve allergic conjunctivitis (itchy eyes caused by allergies). Pazeo is manufactured by Alcon, the ophthalmology division of Novartis.  

Pazeo is a successor to Alcon’s older eye drops, Pataday (olopatadine ophthalmic solution) 0.1% and Patanol (olopatadine ophthalmic solution) 0.2%.  Pataday is used once daily and Patanol is used twice daily, and both are nearing the end of patent protection. Pazeo is expected to be launched in March 2015. 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

 

Last Updated Sunday, April 23, 2017 - 09:49 AM.